Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2012-01-04 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2012-01-04 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 22, 2011. It reports the entry into a material definitive agreement between Ligand Pharmaceuticals and Hospira, Inc. The content focuses on the description of the license and supply agreement, including financial terms and contract duration. There are no financial statements or detailed financial performance data presented. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing reporting a material event (contract agreement) as required by the SEC. The document length is 4050 characters, which is relatively short and consistent with a Form 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2011-12-27 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events or agreements by the company. The text describes the entry into a material definitive agreement (a license and supply agreement with Eli Lilly) and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, only a description of the agreement and reference to future filings. The document is not an annual or quarterly report, nor an earnings release, nor a management discussion. It is a regulatory announcement of a material contract event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-12-21 English
SC 13G/A Filing
Major Shareholding Notification
2011-12-12 English
SC 13G/A Filing
Major Shareholding Notification
2011-11-23 English
4 Filing
Director's Dealing
2011-11-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.